Two Experimental HIV Vaccine Regimens Fail To Lower Infections In Three-Year Trial Compared To Participants Taking A Placebo In Eastern, Southern Africa, Study Shows

Healio (8/1, Feller) reports, “Two experimental HIV vaccine regimens failed to reduce infections in a 3-year trial in eastern and southern Africa compared with participants who were taking a placebo, some of whom were on oral PrEP, according to a study.” Researchers came to this conclusion after assigning “participants randomly into three groups: one group received a combined DNA vaccine (DNA-HIV-PT123) and protein vaccine (AIDSVAX B/E), one received the DNA vaccine, a modified nondividing virus vector (MVA-CMDR) and a protein-based vaccine (CN54gp140), and a placebo group received saline over the course of a four-injection schedule of visits.” The findings were presented at the International AIDS Conference.